Psych Vivas · Psychopharmacology — clozapine
Clozapine — consultant viva
Fellowship viva covering TRS entry, evidence, titration, lethal adverse effects, CYP1A2, levels, and rechallenge principles.
On this page & tools
Target exams
Station structure
Time: 8–10 minutes. Depth: consultant teaching registrar. Expect TRRIP language, named trials, and automatic safety protocols without inventing one country's exact ANC cut-offs as universal law.[1][8]
Core questions and model points
-
When is clozapine indicated? TRS after two adequate adherent trials (TRRIP); high suicide risk schizophrenia (InterSePT). Kane principle of superiority in TRS. Siskind: offer earlier because response rates are meaningful.[1][2][3][8]
-
How do you start safely? Baseline bloods/metabolic/ECG/cardiac markers per protocol; start 12.5 mg; slow titration; weekly haematology early per local registry; first-month myocarditis vigilance.[4]
-
Week-3 fever and tachycardia? Myocarditis until proven otherwise — stop clozapine, ECG, CRP, troponin, cardiology. Risk amplifiers: rapid titration, valproate.[4]
-
Smoking cessation on the ward? CYP1A2 induction falls; levels rise; reduce dose and monitor levels/toxicity.[6]
-
Constipation? CIGH can kill; prevent from day one; escalate ileus as surgical emergency and stop clozapine.[5]
-
Five days missed? Re-titrate from low dose per product guidance — do not resume full maintenance immediately.[6]
-
Rechallenge after neutropenia? Specialist, reaction-specific; Manu-type case-series guidance; not automatic; haematology partnership.[7]
Pass criteria
- TRRIP and Kane/InterSePT/Siskind one-liners correct.[1][2][3][8]
- Myocarditis and CIGH recognised as stop-and-escalate emergencies.[4][5]
- Smoking/CYP1A2 and missed-dose re-titration automatic in speech.[6]
- Region-aware haematology principles without fabricated universal cut-offs.[1]
References
- [1]Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology Am J Psychiatry, 2017.PMID 27919182
- [2]Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 1988.PMID 3046553
- [3]Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry, 2003.PMID 12511175
- [4]Ronaldson KJ, Taylor AJ, Fitzgerald PB, et al. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry, 2010.PMID 20361910
- [5]Palmer SE, McLean RM, Ellis PM, et al. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry, 2008.PMID 18452342
- [6]Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol, 2004.PMID 14709950
- [7]Manu P, Lapitskaya Y, Shaikh A, et al. Clozapine Rechallenge After Major Adverse Effects: Clinical Guidelines Based on 259 Cases. Am J Ther, 2018.PMID 29505490
- [8]Siskind D, Siskind V, Kisely S Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis Can J Psychiatry, 2017.PMID 28655284